GlaxoSmithKline : Vaccine and consumer activities once again set the pace
>Vaccines and consumer businesses drive growth - GSK yesterday reported its Q1 2019 results intraday. Operating profit significantly exceeded expectations. Once again buoyed by the vaccines division (Shingrix and meningitis) and by a solid quarter in OTC (+4% at constant currency (cc)), the group benefit from a favourable product-mix effect for the margin. This effect partly offset the decline of Advair in the US (-61% cc) and a significant increase in R&D costs (acqu...GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.